Autoregulation Assessment During Liver Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Johns Hopkins University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Charles W. Hogue, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01425385
First received: August 26, 2011
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

Patients with liver failure undergoing liver transplantation often have clinical or sub-clinical encephalopathy that may lead to increased intracranial pressure. The latter may lead to abnormal regulation of blood flow to the brain (cerebral autoregulation) complicating patient management during and after general anesthesia. The current methods for monitoring for elevated intracranial pressure are invasive and, thus, limited to severe encephalopathy. In this study the investigators will evaluate the potential utility of monitoring cerebral blood flow autoregulation non-invasively using near infra-red spectroscopy in patients undergoing liver transplantation.


Condition Intervention
Liver Failure
Liver Transplantation
Encephalopathy
Other: Near infrared spectroscopy monitoring
Other: Autoregulation monitoring

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-Invasive Assessment of Cerebral Blood Flow Autoregulation in Patients Undergoing Liver Transplantation

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Estimated Enrollment: 20
Study Start Date: September 2011
Groups/Cohorts Assigned Interventions
Autoregulation monitoring
Patients will be grouped into Meld Score
Other: Near infrared spectroscopy monitoring
This is an observational study without interventions
Other Name: Cerebral oximetry index and hemaglobin volume index
Other: Autoregulation monitoring
There are no interventions in this observational study
Other Name: Cerebral oximetry

Detailed Description:

Hepatic encephalopathy complicating chronic liver failure in patients undergoing liver transplantation increases the risk for adverse outcomes including mortality. Even mild hepatic encephalopathy may not be recognized clinically without specific testing but can be associated with impaired functional status and reduced quality of life before liver transplantation. The changes that can be seen in chronic liver failure, (cerebral edema and increased intracranial pressure) can adversely affect cerebral blood flow autoregulation that may predispose to brain injury during the multiple hemodynamic perturbations that occur during and after liver transplantation. Currently, invasive monitoring with an intracranial "bolt" is the only method to aggressively manage patients with elevated intracranial pressure from acute liver failure and hepatic encephalopathy. The placement of an intracranial pressure catheter in patient with liver failure is associated with a risk of brain hemorrhage due the presence of a coagulopathy. Further, the risk of this type of monitoring outweighs the benefits in the patients with milder or subclinical forms of hepatic encephalopathy. In this pilot study of 20 patients undergoing liver transplantation we will evaluate the feasibility of non-invasive monitoring of CBF autoregulation and assess whether autoregulation is impaired in this group of patients. We hypothesize that cerebral blood flow autoregulation is impaired in patients undergoing liver transplantation based on severity of liver disease. In this situation, improved patient monitoring would allow clinicians to maintain arterial blood pressure above an individual's lower limit of cerebral blood flow autoregulation that might prevent devastating brain injury during and after surgery. Cerebral blood flow autoregulation can be continuously monitored by evaluating the correlation coefficient between cerebral blood flow velocity measured with transcranial Doppler and arterial blood pressure. Our group has developed a novel method of autoregulation monitoring using near infrared spectroscopy that allows continuous monitoring of autoregulation with the cerebral oximetry index and the hemoglobin volume index(, a moving linear correlation coefficient between cortical tissue oxygen saturation and hemoglobin level with arterial blood pressure, respectively. The latter approach is more practical and would allow widespread autoregulation monitoring in diverse clinical settings. A secondary hypothesis of this study is that near infrared spectroscopy-based monitoring of CBF autoregulation will provide an accurate assessment of the limits of autoregulation compared with the more clinically challenging transcranial Doppler methods .

Specific Aims:

  1. To assess whether patients undergoing liver transplantation have impaired cerebral blood flow autoregulation.
  2. To evaluate whether non-invasive monitoring of cerebral blood flow autoregulation with cerebral oximetry index and hemoglobin volume index can identify the lower limit of autoregulation within 10 mmHg compared with that measured with transcranial Doppler.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

In this pilot study we will enroll 20 patients undergoing orthotopic liver transplantation at The Johns Hopkins Hospital. Patients will receive standard care during the procedure. Study related procedures are non-invasive and observational. There will be no interventions based on the results of the study data. The study will include only the immediate operative period. The patients will have transcranial Doppler monitoring and near infrared spectroscopy monitoring during surgery beginning before anesthesia induction and continued until the end of surgery.

Criteria

Inclusion Criteria:

-Age > 18 years old and undergoing liver transplantation.

Exclusion Criteria:

  • Clinical instability as judged by the attending physicians whereby autoregulation monitoring may interfere with clinical care.
  • Women of child bearing potential require a negative urine HCG test to be enrolled.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01425385

Contacts
Contact: Charles W Hogue, MD (410) 614-1516 chogue2@jhmi.edu
Contact: Michelle Parish, BSN maparish@jhmi.edu

Locations
United States, Maryland
The Johns Hopkins Hospital Not yet recruiting
Baltimore, Maryland, United States, 21287
Principal Investigator: Charles W Hogue, MD         
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Charles W Hogue, MD The Johns Hopkins University School of Medicine
  More Information

No publications provided by Johns Hopkins University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Charles W. Hogue, Professor of Anesthesiology & Critical Care Medicine, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT01425385     History of Changes
Other Study ID Numbers: JHU-010
Study First Received: August 26, 2011
Last Updated: August 29, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Johns Hopkins University:
liver failure
liver transplantation

Additional relevant MeSH terms:
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on September 18, 2014